| Q52648540 | A 'fly in the ointment': cutaneous infestation by Musca domestica. |
| Q92134596 | A Survey on Inhibitory Effect of Whole-Body Extraction and Secretions of Lucilia sericata's Larvae on Leishmania major In vitro |
| Q33602668 | A novel approach to the antimicrobial activity of maggot debridement therapy |
| Q28541139 | A novel serine protease secreted by medicinal maggots enhances plasminogen activator-induced fibrinolysis |
| Q30539703 | A thin polymer membrane, nano-suit, enhancing survival across the continuum between air and high vacuum |
| Q53734502 | An unusual evolution of a case of Klippel-Trenaunay syndrome. |
| Q46680495 | Antibacterial properties of larval secretions of the blowfly, Lucilia sericata |
| Q92029462 | Antiviral and virucidal activities of Lucilia cuprina maggots' excretion/secretion (Diptera: Calliphoridae): first work |
| Q39343686 | Benefits of maggot debridement therapy on leg ulcers: a literature review |
| Q38265634 | Biofilms in wounds: a review of present knowledge |
| Q50493107 | Blow fly Lucilia sericata nuclease digests DNA associated with wound slough/eschar and with Pseudomonas aeruginosa biofilm. |
| Q107745041 | Calliphoridae Flies in Medical Biotechnology |
| Q52729331 | Clinical research on the bio-debridement effect of maggot therapy for treatment of chronically infected lesions. |
| Q38076419 | Complement activation and inhibition in wound healing |
| Q58729430 | Coumarin Reduces Virulence and Biofilm Formation in by Affecting Quorum Sensing, Type III Secretion and C-di-GMP Levels |
| Q41352433 | Detection and partial characterization of antifungal bioactivity from the secretions of the medicinal maggot, Lucilia sericata |
| Q38675562 | Does maggot therapy promote wound healing? The clinical and cellular evidence |
| Q40088134 | Effective wound bed preparation using maggot debridement therapy for patients with critical limb ischaemia |
| Q90730645 | Embryonic mesothelial-derived hepatic lineage of quiescent and heterogenous scar-orchestrating cells defined but suppressed by WT1 |
| Q48263073 | Endotoxin testing of a wound debridement device containing medicinal Lucilia sericata larvae |
| Q40045313 | Evaluation of blowfly larvae (Diptera: Calliphoridae) as possible reservoirs and mechanical vectors of African swine fever virus. |
| Q40755745 | Evaluation of conventional therapeutic methods versus maggot therapy in the evolution of healing of tegumental injuries in Wistar rats with and without diabetes mellitus |
| Q39654018 | Expression of a cGMP compatible Lucilia sericata insect serine proteinase debridement enzyme |
| Q33738952 | Fatty acid extracts from Lucilia sericata larvae promote murine cutaneous wound healing by angiogenic activity |
| Q51785752 | First Record of Larval Secretions of Cochliomyia macellaria (Fabricius, 1775) (Diptera: Calliphoridae) Inhibiting the Growth of Staphylococcus aureus and Pseudomonas aeruginosa. |
| Q46250741 | Guidelines for Burn Care Under Austere Conditions: Surgical and Nonsurgical Wound Management. |
| Q38302942 | Helminthes and insects: maladies or therapies |
| Q41295893 | Histological patterns in healing chronic wounds using Cochliomyia macellaria (Diptera: Calliphoridae) larvae and other therapeutic measures. |
| Q43586896 | Induction of antibacterial activity in larvae of the blowflyLucilia sericataby an infected environment |
| Q39204788 | Insect Artifacts Are More than Just Altered Bloodstains |
| Q34658264 | Larval therapy for leg ulcers (VenUS II): randomised controlled trial. |
| Q24647161 | Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential |
| Q42283504 | Lucilia sericata chymotrypsin disrupts protein adhesin-mediated staphylococcal biofilm formation |
| Q28247168 | Maggot Therapy: The Science and Implication for CAM Part I-History and Bacterial Resistance |
| Q33712173 | Maggot debridement therapy for a patient with critical limb ischaemia and severe cardiac dysfunction: possibility of limb salvage |
| Q35600044 | Maggot debridement therapy in the treatment of complex diabetic wounds |
| Q35105539 | Maggot debridement: an alternative method for debridement. |
| Q28278228 | Maggot excretions affect the human complement system |
| Q51343366 | Maggot therapy in the treatment of wounds of exposed knee prostheses. |
| Q37886070 | Maggot therapy in wound management in modern era and a review of published literature |
| Q28272808 | Maggot therapy takes us back to the future of wound care: new and improved maggot therapy for the 21st century |
| Q36585047 | Maggot therapy: the science and implication for CAM part II-maggots combat infection |
| Q38162351 | Maximising the secondary beneficial effects of larval debridement therapy |
| Q21284686 | Mechanisms of maggot-induced wound healing: what do we know, and where do we go from here? |
| Q38152372 | Multiple actions of Lucilia sericata larvae in hard-to-heal wounds: larval secretions contain molecules that accelerate wound healing, reduce chronic inflammation and inhibit bacterial infection |
| Q93165164 | New Insights Into Culturable and Unculturable Bacteria Across the Life History of Medicinal Maggots Lucilia sericata (Meigen) (Diptera: Calliphoridae) |
| Q36784772 | Next Generation Sequencing Identifies Five Major Classes of Potentially Therapeutic Enzymes Secreted by Lucilia sericata Medical Maggots |
| Q33226892 | Options for debridement in the therapy of chronic wounds |
| Q39280633 | Pain related to maggot debridement therapy |
| Q55265628 | Pharmacological Properties of the Medical Maggot: A Novel Therapy Overview. |
| Q95642648 | Practical context of enzymatic treatment for wound healing: A secreted protease approach (Review) |
| Q52682239 | Proteolytic activity in salivary gland products of sheep bot fly (Oestrus ovis) larvae. |
| Q48317712 | Quality control of a medicinal larval (Lucilia sericata) debridement device based on released gelatinase activity. |
| Q33634334 | Recent advances in developing insect natural products as potential modern day medicines |
| Q52719126 | Recombinant Lucilia sericata chymotrypsin in a topical hydrogel formulation degrades human wound eschar ex vivo. |
| Q58305574 | Risques et valorisation des insectes dans l’alimentation humaine et animale |
| Q41464670 | Selective Antibiofilm Effects of Lucilia sericata Larvae Secretions/Excretions against Wound Pathogens. |
| Q40917061 | Slough and biofilm: removal of barriers to wound healing by desloughing |
| Q107744115 | Surgical maggots and the history of their medical use |
| Q38548116 | TIME management by medicinal larvae |
| Q36339466 | Targeting microbial biofilms using Ficin, a nonspecific plant protease. |
| Q43415589 | The cost of wound debridement: a Canadian perspective |
| Q52836638 | The impacts of larval density and protease inhibition on feeding in medicinal larvae of the greenbottle fly Lucilia sericata. |
| Q43196408 | The influence of maggot excretions on PAO1 biofilm formation on different biomaterials |
| Q40443004 | The transcriptional responses of cultured wound cells to the excretions and secretions of medicinal Lucilia sericata larvae. |
| Q26748518 | Traditional Therapies for Skin Wound Healing |
| Q35640886 | Use of maggot therapy for treating a diabetic foot ulcer colonized by multidrug resistant bacteria in Brazil |
| Q46858306 | Wound debridement potential of glycosidases of the wound-healing maggot, Lucilia sericata |
| Q52641334 | [Wound debridement and treatment of ulcus cruris. Conservative and operative therapeutic procedures]. |